Total amount: € 0,00
HOW TO ORDER
MINERVA UROLOGICA E NEFROLOGICA
A Journal on Nephrology and Urology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
ACUTE KIDNEY INJURY
Minerva Urologica e Nefrologica 2009 September;61(3):249-56
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium
Ecke T. H. 1, Gerullis H. 2, Bartel P. 1, Koch S. 3, Ruttloff J. 1
1 HELIOS Hospital, Department of Urology,Bad Saarow, Germany
2 Lukas Hospital, Department of Urology,Neuss, Germany
3 HELIOS Hospital, Institute of Pathology,Bad Saarow, Germany
Aim. The objective of this study was to evaluate the adjuvant chemotherapy with gemcitabine, paclitaxel, and cisplatin for urothelial carcinoma.
Methods. Twenty-seven patients with invasive transitional cell carcinoma of the urothelium were treated between 2001 and 2007. All patients received chemotherapy with intravenous gemcitabine at a dose of 1000 mg/mÇ on Days 1 and 8, intravenous paclitaxel at a dose of 80 mg/mÇ on Days 1 and 8, and intravenous cisplatin at a dose of 50 mg/mÇ on Day 2. Treatment courses were repeated every 21 days.
Results. Median follow-up period was 32.5 months. Six patients came to progressive disease. The median overall survival was not reached, and the actuarial 1-year and 2-year survival rates were 89% and 67% respectively. The median progression-free survival was 10.0 months. Median survival time for patients with ECOG status 0, and 1 was 52.0, and 22.0 months respectively. Grade 4 neutropenia occurred in 18.5% of patients, but there was no treatment related mortality.
Conclusion. The combination of gemcitabine, paclitaxel, and cisplatin is a highly effective and tolerable regimen for patients with invasive transitional cell carcinoma of the urothelium. This treatment should be considered as a suitable option that deserves further prospective evaluation. ECOG performance status is an important predictive factors for survival.